List of Excipients in Branded Drug JESDUVROQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	JESDUVROQ	daprodustat	0173-0897	CELLULOSE, MICROCRYSTALLINE	2028-12-11
GlaxoSmithKline LLC	JESDUVROQ	daprodustat	0173-0897	CROSCARMELLOSE SODIUM	2028-12-11
GlaxoSmithKline LLC	JESDUVROQ	daprodustat	0173-0897	FERRIC OXIDE RED	2028-12-11
GlaxoSmithKline LLC	JESDUVROQ	daprodustat	0173-0897	FERRIC OXIDE YELLOW	2028-12-11
GlaxoSmithKline LLC	JESDUVROQ	daprodustat	0173-0897	FERROSOFERRIC OXIDE	2028-12-11
GlaxoSmithKline LLC	JESDUVROQ	daprodustat	0173-0897	HYPROMELLOSE	2028-12-11
GlaxoSmithKline LLC	JESDUVROQ	daprodustat	0173-0897	MAGNESIUM STEARATE	2028-12-11

JESDUVROQ Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 12, 2026

JESDUVROQ (daprodustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved by the FDA for anemia caused by chronic kidney disease in adults who have been receiving dialysis for at least three months. Its commercial opportunity depends on oral convenience, dialysis-center adoption, renal-anemia treatment protocols, and the ability to differentiate generic or licensed products through excipient design, packaging, and supply reliability. The core formulation is a conventional immediate-release tablet, leaving room for low-cost generic development and selected premium formulations.

What is JESDUVROQ and how is it used?

JESDUVROQ contains daprodustat, a small-molecule HIF-PHI developed by GlaxoSmithKline. The FDA approved it on February 1, 2023, under NDA 215192.[1]

Attribute	JESDUVROQ data
Active ingredient	Daprodustat
Drug class	HIF prolyl hydroxylase inhibitor
Sponsor	GlaxoSmithKline
FDA approval	February 1, 2023
FDA indication	Anemia due to CKD in adults on dialysis for at least three months
Dosage form	Immediate-release oral tablet
Strengths	25 mg, 50 mg, 100 mg, 150 mg
Administration	Once daily, with or without food
Primary competitors	Erythropoiesis-stimulating agents, roxadustat outside the U.S., vadadustat, iron therapy
Key safety issues	Cardiovascular and thromboembolic risk, hypertension, malignancy-related concerns, liver injury monitoring

Daprodustat increases endogenous erythropoietin production through HIF pathway activation. Unlike injectable epoetin products, it is administered orally. The approved U.S. indication is narrower than the broader dialysis and nondialysis anemia populations initially targeted during development.[1]

What excipients are used in JESDUVROQ tablets?

The JESDUVROQ tablet uses a standard immediate-release excipient system. The U.S. prescribing information identifies the formulation as containing lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and film-coating components including polyvinyl alcohol, macrogol, talc, titanium dioxide, and iron oxides.[1]

Formulation function	JESDUVROQ excipient approach	Commercial implication
Diluent	Lactose monohydrate and microcrystalline cellulose	Low-cost, established tablet platform
Disintegrant	Croscarmellose sodium	Supports immediate release
Lubricant	Magnesium stearate	Standard high-volume tableting excipient
Film former	Polyvinyl alcohol	Supports coating uniformity and mechanical protection
Plasticizer or coating aid	Macrogol	Improves film flexibility
Opacifier and pigment	Titanium dioxide and iron oxides	Enables strength differentiation and light protection
Anti-tacking or coating aid	Talc	Supports coating manufacture

The formulation is commercially accessible to generic manufacturers because it does not rely on a specialized lipid system, controlled-release polymer, osmotic delivery device, or biologic stabilization platform.

Does JESDUVROQ use a novel excipient?

No novel excipient is central to the approved formulation. The excipient profile consists of widely used pharmaceutical ingredients with established oral solid-dose manufacturing histories. This limits formulation barriers to entry but also reduces development risk for ANDA applicants.

The formulation strategy has several practical advantages:

• Conventional high-speed tablet compression is possible.
• Standard aqueous or solvent-based film coating equipment can be used.
• The dosage strengths can be manufactured on a common platform.
• Excipient sourcing can be dual-qualified.
• Bioequivalence development should be more predictable than for modified-release products.

The primary formulation risks are not technical novelty. They are content uniformity, dissolution matching, tablet hardness, coating performance, impurity control, and supply-chain consistency.

What excipient opportunities exist for JESDUVROQ?

The largest opportunity is not a direct substitution of the active ingredient. It is development of equivalent or differentiated oral solid-dose products that improve manufacturability, patient acceptability, or supply economics.

Lactose-free formulations

The reference product uses lactose monohydrate. A generic or authorized-generic developer could replace lactose with mannitol, anhydrous dibasic calcium phosphate, spray-dried microcrystalline cellulose, or a co-processed filler.

A lactose-free platform could support:

• Patients with lactose intolerance or excipient sensitivity.
• Institutional formularies seeking a broader dietary compatibility profile.
• Export markets with different labeling preferences.
• A differentiated product claim where formulation patents do not block substitution.

The replacement would require dissolution, stability, impurity, and bioequivalence evaluation. Lactose substitution can alter tablet compactability, moisture behavior, and disintegration.

Low-moisture and high-stability platforms

Dialysis patients often use multiple medicines, and products may be stored in home environments rather than tightly controlled hospital pharmacies. A low-moisture formulation using anhydrous excipients or desiccant-compatible packaging could improve stability margins.

Potential approaches include:

• Anhydrous diluents.
• Moisture-barrier blister packaging.
• High-barrier HDPE bottles with desiccant.
• Lower-permeability film coatings.
• Packaging configurations that separate multiple strengths.

This opportunity is commercially relevant if daprodustat demonstrates sensitivity to humidity, oxidation, or polymorphic conversion during long-term storage. The reference label alone does not establish that such a platform is required.

Tablet-size reduction

The four approved strengths create opportunities to reduce tablet burden through higher drug loading or improved excipient selection. A smaller tablet could improve adherence, particularly in dialysis patients who already take phosphate binders, antihypertensives, iron products, and other chronic medicines.

Potential technologies include:

• Direct compression with high-functionality fillers.
• Co-processed excipients.
• Dry granulation.
• Roller compaction.
• Improved powder flow and segregation control.

A smaller tablet cannot compromise dissolution or dose uniformity. The most commercially credible approach is a size-reduced immediate-release tablet rather than a new modified-release product.

Alternative coating and color systems

JESDUVROQ uses film-coated tablets. A generic developer could use a functionally equivalent coating with different pigments, lower titanium dioxide content, or a more robust moisture barrier.

Relevant commercial objectives include:

• Clearer strength differentiation.
• Lower coating weight.
• Reduced coating defects.
• Easier global color compliance.
• Lower cost per tablet.

Coating changes are unlikely to create durable exclusivity by themselves unless supported by a specific manufacturing or composition patent.

Pediatric and swallowing-oriented dosage forms

The current U.S. approval is for adults. A dispersible tablet, oral granule, or liquid formulation could support future pediatric or geriatric development if the clinical indication expands.

The main technical challenges are:

• Daprodustat solubility and dose uniformity.
• Taste masking.
• Chemical stability in aqueous media.
• Compatibility with enteral feeding.
• Accurate low-dose administration.
• Interaction with minerals and binders.

These products would face clinical and regulatory requirements beyond a conventional generic tablet. Their commercial value depends on label expansion and payer coverage.

When does JESDUVROQ lose exclusivity?

JESDUVROQ received five years of U.S. new chemical entity exclusivity, subject to statutory qualifications. Based on the February 1, 2023 approval date, the NCE exclusivity period is expected to run until February 1, 2028. ANDA applicants may generally submit Paragraph IV patent challenges after four years, potentially beginning February 1, 2027, if applicable patents remain listed.[2]

Milestone	Expected timing
FDA approval	February 1, 2023
Four-year ANDA Paragraph IV filing window	February 1, 2027
Five-year NCE exclusivity end	February 1, 2028
Earliest routine generic approval absent blocking patents	February 1, 2028
Possible 180-day first-filer period	Depends on valid Paragraph IV filing and forfeiture events

Patent expiration and regulatory exclusivity are separate. A listed patent can delay approval after NCE exclusivity ends. The Orange Book, FDA patent listing records, and relevant USPTO patent-family records control the final generic-entry analysis.[2,3]

What is the Orange Book status of JESDUVROQ?

The Orange Book is the controlling FDA source for patents listed against the approved daprodustat product. A commercial diligence review should distinguish:

1. Patents covering daprodustat itself.
2. Composition or formulation patents.
3. Method-of-use patents.
4. Manufacturing or process patents.
5. Patents that have expired, been delisted, or no longer block ANDA approval.
6. Regulatory exclusivity that operates independently of patent rights.

The FDA label establishes the approved formulation and indication, but it does not provide a complete patent-rights analysis. Generic entry risk should therefore be assessed against the current Orange Book record and the prosecution history of each listed patent.[2]

What Paragraph IV challenges and litigation affect JESDUVROQ?

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. If the patent holder files an infringement action within the statutory period after receiving notice, FDA approval may be subject to a 30-month stay, subject to court rulings and statutory exceptions.[4]

For JESDUVROQ, the commercial risk framework is:

Event	Effect on market entry
ANDA filed with Paragraph IV certification	Creates potential early generic challenge
Patent owner does not sue within the statutory period	No automatic 30-month stay from that patent
Patent litigation filed	Potential 30-month approval stay
Generic wins or patent is not infringed	Earlier approval may follow
Patent survives and is infringed	Approval may be delayed until patent expiry or settlement
First successful Paragraph IV filer	May obtain 180-day generic exclusivity

No public litigation conclusion should be inferred solely from an ANDA filing or a patent listing. Settlements can permit an agreed launch date, authorized-generic supply, or other commercial terms. They can also preserve branded market share until late in the patent term.

How strong is the JESDUVROQ patent estate?

The estate is likely to be stronger for the active molecule and clinical use than for the excipient platform. Conventional excipients provide limited differentiation and are generally vulnerable to substitution in ANDA development.

Active-ingredient protection

Daprodustat is a synthetic small molecule, so its primary protection would normally arise from composition-of-matter patents and related HIF-PHI patent families. These rights can create a meaningful barrier through the patent term, particularly if the claims cover the molecule, stereochemistry, salts, or broad pharmaceutical uses.

Method-of-use protection

Method-of-use claims may cover treatment of anemia associated with CKD, dialysis populations, dosing regimens, or patient-selection criteria. Their value depends on claim scope and whether the ANDA label can be carved out without removing the generic's commercially necessary indication.

Formulation protection

The approved tablet uses conventional excipients. A formulation patent would need to distinguish a specific composition, ratio, process, dissolution profile, stability result, or manufacturing method. A generic applicant may avoid infringement by using a different excipient system while maintaining bioequivalence.

Manufacturing protection

Process patents may cover synthesis, purification, polymorph control, particle-size distribution, or impurity reduction. These patents can matter to API suppliers even when they do not directly prevent a finished-dose ANDA. A reliable alternative API route can therefore become a licensing and supply-chain advantage.

What commercial opportunities exist for generic and specialty manufacturers?

Generic tablets

The most direct opportunity is a conventional daprodustat tablet after applicable exclusivity and patent barriers expire. Generic manufacturers can compete through:

• Lower acquisition cost.
• Multi-strength supply.
• Reliable dialysis-center distribution.
• Unit-dose packaging.
• Broad wholesaler coverage.
• Lactose-free or size-reduced tablets.

Authorized generic or co-commercialization

GSK could use an authorized-generic strategy to retain channel presence after generic entry. A third-party manufacturer could supply tablets under license, creating an opportunity for:

• Contract manufacturing.
• Secondary packaging.
• Regional commercialization.
• Hospital and dialysis-network supply.
• API and finished-dose dual sourcing.

Excipient and contract-manufacturing supply

Excipient suppliers can target generic developers with:

• Co-processed direct-compression systems.
• Low-moisture tableting platforms.
• Pigment and coating systems.
• High-throughput granulation services.
• Stability-indicating packaging.
• Analytical methods for dissolution and impurity control.

The strongest value proposition is reduced development time and manufacturing variability, not exclusivity based on a single excipient.

Geographic expansion

The U.S. label is limited to adults on dialysis for at least three months. Commercial opportunities in Europe, Japan, and other markets depend on local authorization and the clinical positioning of daprodustat against ESAs and other HIF-PHIs. Regional opportunities may include:

• Dialysis-center formularies.
• Oral anemia treatment for patients reluctant to use injections.
• Markets with limited access to injectable ESAs.
• Local contract manufacturing.
• Country-specific tablet and packaging configurations.

Roxadustat has broader international exposure in several markets, while vadadustat and daprodustat compete for differentiated positions based on safety, dosing, reimbursement, and dialysis use.[5,6]

How does JESDUVROQ compare with competing anemia therapies?

Product class	Route	Main commercial advantage	Main limitation
JESDUVROQ	Oral	Avoids routine injection administration	U.S. indication limited to established dialysis patients
ESAs	Injectable	Established clinical use and broad provider familiarity	Injection burden and administration logistics
Roxadustat	Oral	HIF-PHI platform with international use	U.S. regulatory and market-position differences
Vadadustat	Oral	HIF-PHI competitor for CKD anemia	Differing label and safety profile
IV iron	Intravenous	Direct iron replacement	Does not replace erythropoietic stimulation in all patients
Oral iron	Oral	Low-cost and accessible	Tolerability and absorption limitations

JESDUVROQ's commercial position is strongest where oral administration has operational value and where dialysis providers can incorporate the drug into established anemia-management protocols. It is weaker where injectable ESA procurement is deeply standardized or where reimbursement does not reward oral substitution.

What revenue exposure and launch risks matter?

GSK does not generally report JESDUVROQ as a standalone revenue segment in its main financial disclosures. Revenue exposure is therefore assessed through prescription growth, payer coverage, dialysis-network adoption, and the rate of substitution from ESAs rather than through a separately reported product segment.[7]

The main commercial risks are:

• Narrow U.S. labeling.
• Cardiovascular safety monitoring.
• Competition from established ESAs.
• Reimbursement restrictions.
• Slow dialysis-center protocol adoption.
• Generic entry after regulatory exclusivity.
• Limited differentiation from conventional tablet excipients.
• Potential supply constraints for API or specialized analytical testing.

Key Takeaways

• JESDUVROQ is an immediate-release daprodustat tablet approved in the U.S. in February 2023 for adults with CKD anemia who have been on dialysis for at least three months.
• Its excipient system is conventional and includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and standard film-coating materials.
• Generic formulation barriers are moderate to low because the product does not depend on a complex delivery system.
• The most credible formulation opportunities are lactose-free tablets, lower-moisture systems, smaller tablets, improved coatings, and differentiated packaging.
• The five-year NCE exclusivity period is expected to end on February 1, 2028, with possible Paragraph IV filings beginning February 1, 2027.
• Active-molecule, method-of-use, formulation, and process patents must be reviewed separately through the Orange Book and USPTO records.
• Commercial opportunities include generic tablets, authorized-generic supply, contract manufacturing, excipient platforms, dialysis-network distribution, and international licensing.
• The principal market constraint is the narrow U.S. dialysis indication, not tablet manufacturing complexity.

FAQs

Can a generic JESDUVROQ use different excipients?

Yes. An ANDA applicant generally may use a different excipient system if the product meets pharmaceutical equivalence, bioequivalence, quality, dissolution, stability, and labeling requirements.

Is lactose-free daprodustat commercially attractive?

It can be attractive as a differentiated generic, particularly for institutional buyers and patients who prefer to avoid lactose. Its value depends on tablet size, cost, stability, and whether the formulation achieves a clean bioequivalence profile.

Could JESDUVROQ be reformulated as an extended-release product?

Yes, technically, but an extended-release product would require new formulation development, pharmacokinetic characterization, and potentially new clinical evidence. It would not automatically qualify as an equivalent version of the approved immediate-release tablet.

Does a formulation patent automatically block a daprodustat generic?

No. Blocking effect depends on claim scope, validity, infringement, listing status, and the generic's formulation. A generic can sometimes design around a formulation patent by changing excipients, ratios, coating materials, or manufacturing steps.

Are biosimilars relevant to JESDUVROQ?

No. Daprodustat is a small-molecule drug, so competition would proceed through the ANDA generic pathway rather than the biosimilar pathway under the Public Health Service Act.

References

1. U.S. Food and Drug Administration. (2023). JESDUVROQ (daprodustat) prescribing information. GlaxoSmithKline.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application. https://www.fda.gov/drugs

5. European Medicines Agency. (n.d.). HIF-prolyl hydroxylase inhibitors and medicines for anemia associated with chronic kidney disease. https://www.ema.europa.eu/

6. U.S. Food and Drug Administration. (2024). Drug approval and safety information for treatments of anemia in chronic kidney disease. https://www.fda.gov/

7. GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/financial-results/